, Volume 10, Issue 2, pp 129–133 | Cite as

Normal levels of serum IGF-I: determinants and validity of current reference ranges

  • G. BrabantEmail author
  • H. Wallaschofski


Insulin like growth factor I (IGF-I) represents the key marker for the evaluation of Growth hormone (GH) status. As a large number of determinants including age, gender, genetic factors, nutrition, and disease states influence IGF-I serum levels, accurate normative data are essential to translate patient data into diagnostic meaning or even use IGF-I levels for adequate monitoring of patients with an over- or under-active GH axis. Even though reference ranges have been developed in large cohorts of healthy subjects, the dependency of these data on a given assay technology argues for assay specific normative data for IGF-I.


IGF-I Gender Age Genetics Nutrition Disease dependency 


  1. 1.
    Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19(6):717–797PubMedCrossRefGoogle Scholar
  2. 2.
    Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society (2000) GH Research Society. J Clin Endocrinol Metab 85(11):3990–3993CrossRefGoogle Scholar
  3. 3.
    Shalet SM, Toogood A, Rahim A, Brennan BM (1998) The diagnosis of growth hormone deficiency in children and adults. Endocr Rev 19(2):203–223PubMedCrossRefGoogle Scholar
  4. 4.
    Brabant G (2003) Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. Eur J Endocrinol 148(Suppl 2):S15–S20PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen P (2006) Overview of the IGF-I system. Horm Res 65(Suppl 1):3–8PubMedCrossRefGoogle Scholar
  6. 6.
    Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20(6):761–787PubMedCrossRefGoogle Scholar
  7. 7.
    Yakar S, Sun H, Zhao H, Pennisi P, Toyoshima Y, Setser J, Stannard B, Scavo L, Leroith D (2005) Metabolic effects of IGF-I deficiency: lessons from mouse models. Pediatr Endocrinol Rev 3(1):11–19PubMedGoogle Scholar
  8. 8.
    Brabant G, von zur Muhlen A, Wuster C, Ranke MB, Kratzsch J, Kiess W, et al (2003) Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 60(2):53–60PubMedCrossRefGoogle Scholar
  9. 9.
    Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL (2004) Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 89(5):2271–2274PubMedCrossRefGoogle Scholar
  10. 10.
    Borofsky ND, Vogelman JH, Krajcik RA, Orentreich N (2002) Utility of insulin-like growth factor-1 as a biomarker in epidemiologic studies. Clin Chem 48(12):2248–2251PubMedGoogle Scholar
  11. 11.
    Smith PJ, Spurrell EL, Coakley J, Hinds CJ, Ross RJM, Krainer AR, Chew SL (2002) An exonic splicing enhancer in human IGF-I pre-mRNA mediates recognition of alternative exon 5 by the serine-arginine protein splicing factor-2/alternative splicing factor. Endocrinology 143:146–154PubMedCrossRefGoogle Scholar
  12. 12.
    Hong Y, Brismar K, Hall K, Pedersen NL, de Faire U (1997) Associations between insulin-like growth factor-I (IGF-I), IGF-binding protein-1, insulin and other metabolic measures after controlling for genetic influences: results from middle-aged and elderly monozygotic twins. J Endocrinol 153(2):251–257PubMedCrossRefGoogle Scholar
  13. 13.
    Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM (2001) A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 50(3):637–642PubMedCrossRefGoogle Scholar
  14. 14.
    Lofqvist C, Andersson E, Gelander L, Rosberg S, Blum WF, Albertsson Wikland K (2001) Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty. J Clin Endocrinol Metab 86:5870–5876PubMedCrossRefGoogle Scholar
  15. 15.
    Bereket A, Turan S, Omar A, Berber M, Ozen A, Akbenlioglu C, Haklar G (2006) Serum IGF-I and IGFBP-3 levels of Turkish children during childhood and adolescence: establishment of reference ranges with emphasis on puberty. Horm Res 65:96–105PubMedCrossRefGoogle Scholar
  16. 16.
    Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE (1994) Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78:744–752PubMedCrossRefGoogle Scholar
  17. 17.
    Ranke MB, Osterziel KJ, Schweizer R, Schuett B, Weber K, Robbel P, Vornwald A, Blumenstock G, Elmlinger MW (2003) Reference levels of insulin-like growth factor I in the serum of healthy adults: comparison of four immunoassays. Clin Chem Lab Med 41:1329–1334PubMedCrossRefGoogle Scholar
  18. 18.
    Elmlinger MW, Kuhnel W, Weber MM, Ranke MB (2004) Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 42:654–664PubMedCrossRefGoogle Scholar
  19. 19.
    Ho KK, Gibney J, Johannsson G, Wolthers T (2006) Regulating of growth hormone sensitivity by sex steroids: implications for therapy. Front Horm Res 35:115–128PubMedGoogle Scholar
  20. 20.
    Caufriez A, Frankenne F, Hennen G, Copinschi G (1993) Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. Am J Physiol 265(4 Pt 1):E572–E577PubMedGoogle Scholar
  21. 21.
    Monaghan JM, Godber IM, Lawson N, Kaur M, Wark G, Teale D, Hosking DJ (2004) Longitudinal changes of insulin-like growth factors and their binding proteins throughout normal pregnancy. Ann Clin Biochem 41:220–226PubMedCrossRefGoogle Scholar
  22. 22.
    Thissen JP, Ketelsleger JM (1994) Underwood LE Nutritional regulation of the insulin-like growth factors. Endocr Rev 15:80–101PubMedCrossRefGoogle Scholar
  23. 23.
    Lieberman SA, Butterfield GE, Harrison D, Hoffman AR (1994) Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 78:404–410PubMedCrossRefGoogle Scholar
  24. 24.
    Gianotti L, Broglio F, Ramunni J, Lanfranco F, Gauna C, Benso A, Zanello M, Arvat E, Ghigo E (1998) The activity of GH/IGF-I axis in anorexia nervosa and in obesity: a comparison with normal subjects and patients with hypopituitarism or critical illness. Eat Weight Disord 3:64–70PubMedGoogle Scholar
  25. 25.
    Ponzer S, Tidermark J, Brismar K, SoderqvistA&Cederholm T (1999) Nutritional status, insulin-like growth factor-I and quality of life in elderly women with hip fractures. Clin Nutr 18:241–246PubMedCrossRefGoogle Scholar
  26. 26.
    Veldhuis JD, Iranmanesh A (1996) Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: predominant impact of age, obesity, gonadal function, and sleep. Sleep 19(Suppl 10):S221–S224PubMedGoogle Scholar
  27. 27.
    Schneider HJ, Saller B, Klotsche J, Marz W, Erwa W, Wittchen HU, Stalla GK (2006) Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. Eur J Endocrinol 154(5):699–706PubMedCrossRefGoogle Scholar
  28. 28.
    de Boer H, Blok GJ, Voerman B, Derriks P, van der Veen E (1996) Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men. Int J Obes Relat Metab Disord 20(6):580–587PubMedGoogle Scholar
  29. 29.
    Chen JW, Nielsen MF, Caumo A, Vilstrup H, Christiansen JS, Frystyk J (2006) Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis. Eur J Endocrinol 155:285–292PubMedCrossRefGoogle Scholar
  30. 30.
    Barkan AL, Beitins IZ, Kelch RP (1988) Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 67:69–73PubMedCrossRefGoogle Scholar
  31. 31.
    Rabkin R, Schaefer F ( 2004) New concepts: growth hormone, insulin-like growth factor-I and the kidney. Growth Horm IGF Res 14:270–276PubMedCrossRefGoogle Scholar
  32. 32.
    Blum WF, Ranke MB, Kietzmann K, Tonshoff B, Mehls O (1991) Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia. Pediatr Nephrol 5:539–544PubMedCrossRefGoogle Scholar
  33. 33.
    Heald AH, Anderson SG, Ivison F, Laing I, Gibson JM, Cruickshank K (2003) C-reactive protein and the insulin-like growth factor (IGF)-system in relation to risk of cardiovascular disease in different ethnic groups. Atherosclerosis 170:79–86PubMedCrossRefGoogle Scholar
  34. 34.
    Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T (2002) Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106(8):939–944PubMedCrossRefGoogle Scholar
  35. 35.
    Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D (2004) The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 89(1):114–120PubMedCrossRefGoogle Scholar
  36. 36.
    Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353PubMedCrossRefGoogle Scholar
  37. 37.
    Samani AA, Yakar S, LeRoith D, Brodt P (2007) The Role of the IGF System in Cancer Growth and Metastasis: Overview and recent insights. Endocr Rev 28:20–47PubMedCrossRefGoogle Scholar
  38. 38.
    Jenkins PJ, Mukherjee A, Shalet SM (2006) Does growth hormone cause cancer? Clin Endocrinol (Oxf) 64:115–121CrossRefGoogle Scholar
  39. 39.
    von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T (2000) Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 60:4573–4581Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of EndocrinologyChristie HospitalManchesterUK
  2. 2.Department of Gastroenterology, Endocrinology and NutritionUniversity of GreifswaldGreifswaldGermany

Personalised recommendations